AUTHORS: H. Goto, M.D., T. Kushihashi, M.D., H. Kato, M.D., K.T. Benson, M.D., K. Arakawa, M.D.

AFFILIATION: Department of Anesthesiology, University of Kansas Medical Center, Kansas City, Kansas 66103


<u>Introduction</u>: Despite long-standing clinical experience, much controversy still exists concerning the exact mechanisms of the hypotensive effects of protamine sulfate and sodium heparin. It has been postulated that protamine induced hypotension is due in part to the reduction of ionized calcium (Ca++). Unlike protamine, heparin is mostly negatively charged, therefore it might be the heparin that decreases Ca++. The purpose of this study was to examine the interaction of serum Ca++ with protamine and heparin, in vitro and in vivo.

Methods: In vitro study, Part 1: Serum was obtained from mongrel dogs. Solutions of distilled deionized water (DDW) which contained different concentrations of either protamine or heparin (Upjohn Co.) were prepared. 0.1 ml of each solution was added to 0.9 ml of serum, making a total volume of 1.0 ml. Final concentrations of protamine and heparin ranged from 0.025 mg/ml to 1.0 mg/ml. In vitro study, part 2: Protamine (total volume 0.1 ml) and heparin in DDW in DDW (total volume 0.1 ml) were added to 0.8 ml of Heparin serum, making a total volume of 1.0 ml. concentration was fixed at either 0.1 mg/ml or 0.2 mg/ml. Protamine concentration was varied as in Part 1. Serum Ca++ was measured five times for each sample using an ion specific electrode and percent changes of Ca++ levels were plotted against the protamine and heparin concentrations. Twelve mongrel In vivo study: doas were anesthetized, intubated, paralyzed and ventilated with 100% 0_2 and enflurane 0.5--1.0%. A femoral arterial line was placed to allow sampling and to measure blood pressure continuously. After a steady state was achieved, six dogs received protamine 4 mg/kg i.v. over 30 seconds, and six other dogs received heparin 3 mg/kg i.v. over 30 seconds. Arterial blood was sampled for arterial gas tensions and pH, and Ca++ measurements. These were performed 5 min before and 1, 5 and 10 min after administration of each drug. Student's t test was used for statistical analysis.

concentrations, processes (Fig. Results: In vitro study: Even in protamine did not affect serum 1). Heparin, however, decrease the Ca++ in a dose-dependent fashion. Initially decreased Ca++ levels by either 0.1 mg/ml or 0.2 mg/ml of heparin were restored toward the control level by increasing the concentration of protamine (Fig. 2). In vivo study: mean arterial pressure and heart rate decreased significantly at 1 min after protamine administration (Table 1). However, no change in Ca++ levels, blood gas tensions and pH were observed. After heparin administration, none of the parameters changed significantly (Table 2).

<u>Discussion</u>: In vitro part I study indicates that Ca++ does not bind to protamine molecules.

Protamine is in positively charged form in the serum, thus, there will be no electrostatic thus, electrostatic attraction between Ca++ and protamine molecules. On the other hand, Ca++ binds to negatively charged heparin, resulting in the dose-dependent reduction of Ca++. However, in vivo, heparin 3 mg/kg, did not decrease Ca++ level. It is thought that in vivo, Ca++ levels decreased by heparin can restored, ,since muscles and skeletal tissue might In vitro part 2 study indicates release Ca++. that the electrostatic attraction between protamine and heparin is stronger than that between Ca++ suggest that protamine This may heparin. administered for heparin reversal releases Ca++ that has been bound to heparin molecules. Our results of the in vivo protamine study agree with a study by others, in which there was no significant change in Ca++ levels after protamine administration after extracorporeal circulation. conclusion, results of this study indicate the hypotension occasionally observed after protamine or heparin administration is not likely to be related to the ionized calcium.



Circles and vertical bars indicate mean \pm Σ .

Table 1 protamine * P<0.05 n=6(mean ± SE) Ca++(##) Pa0₂ PaCO₂ Ha Control 1.25±0.06 100.0±4.5 122.0±3.3 505.8122.6 36.814.0 7.34±0.02 7.36±0.02 1 min 1.24±0.03 51.0±11.6* 113.6±3.1* 505.2124.1 32.0±3.6 5 min 1.2210.04 89.0118.9 117.214.5 475.2±32.1 35.6±3.3 7.32±0.03 to etn 1.22±0.06 116.3:11.1 119.6:4.8 485.2±26.0 37.9:4.1 7,2910.05

Table 2.			heparin		n=6(mean ± SE)	
	Ca++(nH)	ABP	HR	PaOZ	PaCOZ	pH
Control	1.14±0.10	99.0±5.0	113.2±5.2	508.2:17.0	26.1±1.3	7.42±0.03
1 min	1.18±0.08	102.6±7.1	113.715.2	508,3±19,4	27.7±3.3	7.42±0.03
5 min	1.17±0.08	103.7±7.2	116.4±4.4	497.819.7	26.412.9	7.43±0.03
10 min	1.16±0.07	111.3:8.3	113.6±6.5	512.7±8.9	27.8±3.8	7.44±0.03
efere	nce'					

1. Conahan TJ III, Andrews RW, MacVaugh H III: Cardiovascular effects of protamine sulfate in man. Anesth Analg 60:33-36, 1981